2023

1. Real-World Outcomes of Belantamab Mafodotin for Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results of a Spanish Expanded Access Program (EAP)

   Oncology and Therapy, Vol. 11, Núm. 1, pp. 83-96